| Ytd | -26.25% | |
| 1y | -26.25% |
| Open | 22.46 | Prev Close | 22.26 | Low | 19.38 | High | 22.80 | Mkt Cap | 650.95M |
| Vol | 94.08K | Avg Vol | 95.74K | EPS | -1.34 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 21.24 | 200-d Avg | 23.60 | 1yr Est | 0.00 |
SGP News
SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today
SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.69) per share which missed the analyst
SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(5.72) per share. This is a 24.89 percent
HC Wainwright & Co. analyst Yi Chen initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a
12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Dru
Wall Street analysts changed ratings on top companies. See full list at benzinga.com/analyst-stock-r
Citigroup analyst Yigal Nochomovitz initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy
Leerink Partners analyst Marc Goodman initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a O
Jefferies analyst Dennis Ding initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy ratin
Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all change
Stifel analyst Tom Stephan initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating a
